Long-term administration and efficacy of oxaliplatin with no neurotoxicity in a patient with rectal cancer: Association between neurotoxicity and the GSTP1 polymorphism

Oncology Letters

Volumn 7, Issue 5, 2014, Pages 1499-1502

  Kitade, Hironori ^a   Shimasaki, Takeo ^a,b   Igarashi, Saya ^c   Sakuma, Hiroshi ^c   Mori, Mitsue ^a   Tomosugi, Naohisa ^b   Nakai, Masuo ^c  

^a Houju Memorial Hospital   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c Department of Orthopaedic Surgery   (Japan)

Author keywords

Colorectal cancer; GSTP1; Neurotoxicity; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GLUTATHIONE TRANSFERASE P1; OTASTAT POTASSIUM PLUS TEGAFUR PLUS GIMERACIL; OXALIPLATIN; PANITUMUMAB; PYRIMIDINE ANTAGONIST; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ALLELE; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DNA POLYMORPHISM; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RECTUM CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR RECURRENCE;

EID: 84896309876     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1890     Document Type: Article

References (26)

1. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
2. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004.
3. André T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343-2351, 2004.
4. Watson MA, Stewart RK, Smith GB, Massey TE and Bell DA: Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19: 275-280, 1998.
5. Tournigand C, Cervantes A, Figer A, et al: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 24: 394-400, 2006.
6. Hosokawa A, Ogawa K, Ando T, et al: Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study. Anticancer Res 32: 2545-2550, 2012.
7. Grothey A, Nikcevich DA, Sloan JA, et al: Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 29: 421-427, 2011.
8. Sakurai M, Egashira N, Kawashiri T, Yano T, Ikesue H and Oishi R: Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia. Pain 147: 165-174, 2009.
9. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M and Gamelin E: A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85: 2293-2297, 2001.
10. Wang L, McLeod HL and Weinshilboum RM: Genomics and drug response. N Engl J Med 364: 1144-1153, 2011.
11. Moscow JA, Fairchild CR, Madden MJ, et al: Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 49: 1422-1428, 1989.
12. Goto S, Iida T, Cho S, Oka M, Kohno S and Kondo T: Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic Res 31: 549-558, 1999.
13. Stoehlmacher J, Park DJ, Zhang W, et al: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94: 936-942, 2002.
14. Chen YC, Tzeng CH, Chen PM, et al: Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 101: 530-535, 2010.
15. Hong J, Han SW, Ham HS, et al: Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. Cancer Chemother Pharmacol 67: 1323-1331, 2011.
16. Lecomte T, Landi B, Beaune P, Laurent-Puig P and Loriot MA: Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12: 3050-3056, 2006.
17. Paré L, Marcuello E, Altés A, et al: Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer 99: 1050-1055, 2008.
18. Goekkurt E, Al-Batran SE, Hartmann JT, et al: Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol 27: 2863-2873, 2009.
19. Grothey A, McLeod HL, Green EM, et al: Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity. J Clin Oncol 23 (Suppl 1): abstr 3509, 2005.
20. Ruzzo A, Graziano F, Loupakis F, et al: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25: 1247-1254, 2007.
21. Kanai M, Yoshioka A, Tanaka S, et al: Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer Epidemiol 34: 189-193, 2010.
22. Gamelin L, Capitain O, Morel A, et al: Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 13: 6359-6368, 2007.
23. Kweekel DM, Gelderblom H, Antonini NF, et al: Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer 45: 572-578, 2009.
24. Inada M, Sato M, Morita S, et al: Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther 48: 729-734, 2010.
25. Elsby R, Kitteringham NR, Goldring CE, et al: Increased constitutive c-Jun N-terminal kinase signaling in mice lacking glutathione S-transferase Pi. J Biol Chem 278: 22243-22249, 2003.
26. Grothey A and Sargent D: Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 23: 9441-9442, 2005.